HOOKIPA Pharma Inc. (HOOK)
$1.4
Rating:
Recommendation:
-
| Symbol | HOOK |
|---|---|
| Price | $1.4 |
| Beta | 0.842 |
| Volume Avg. | 3.63M |
| Market Cap | 76.569M |
| Shares () | - |
| 52 Week Range | 1.25-20.0 |
| 1y Target Est | - |
| DCF Unlevered | HOOK DCF -> | |
|---|---|---|
| DCF Levered | HOOK LDCF -> | |
| ROE | -64.80% | Strong Sell |
| ROA | -39.03% | Strong Sell |
| Operating Margin | - | |
| Debt / Equity | 32.30% | Neutral |
| P/E | - | |
| P/B | 0.31 | Neutral |
Latest HOOK news
About
Download (Excel)HOOKIPA Pharma Inc., a clinical stage biopharmaceutical company, develops immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform. The company's lead infectious disease product candidate is HB-101, which is in a randomized double-blinded Phase II clinical trial in patients awaiting kidney transplantation from cytomegalovirus-positive donors. Its lead oncology product candidates are HB-201 and HB-202 that are in Phase I/II clinical trial for the treatment of human papillomavirus 16-positive cancers. The company's preclinical stage products include HB-300 program for prostate cancer; and HB-700 for targeting mutated KRAS in pancreatic, colorectal, and lung cancer. HOOKIPA Pharma Inc. has a collaboration with Gilead Sciences, Inc. to collaborate on preclinical research programs to evaluate potential vaccine products using or incorporating its replicating and non-replicating technology platforms for the treatment, cure, diagnosis, or prevention of Hepatitis B Virus. The company was incorporated in 2011 and is headquartered in New York, New York.